Join

Compare · PFE vs PYPD

PFE vs PYPD

Side-by-side comparison of Pfizer Inc. (PFE) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PFE and PYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $304.95B, about 3612.9x PYPD ($84.4M).
  • Over the past year, PFE is up 17.1% and PYPD is up 81.9% - PYPD leads by 64.7 points.
  • PFE has been more active in the news (10 items in the past 4 weeks vs 3 for PYPD).
  • PFE has more recent analyst coverage (25 ratings vs 6 for PYPD).
PerformancePFE+17.13%PYPD+81.85%
2025-04-28+0.00%2026-04-24
MetricPFEPYPD
Company
Pfizer Inc.
PolyPid Ltd.
Price
$26.98+1.20%
$4.61-1.28%
Market cap
$304.95B
$84.4M
1M return
-1.21%
+5.98%
1Y return
+17.13%
+81.85%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
10
3
Recent ratings
25
6
PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PYPD

PolyPid Ltd.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.